Skip to main content
. 2020 Jan 27;16:125–134. doi: 10.3762/bjoc.16.14

Figure 1.

Figure 1

a) The potent tubulin inhibitor colchicine as a lead scaffold led to the development of the HOTub generation of HTI-based antimitotics (e.g., HOTub-31). Changing the lead scaffold to indanocine led to the development of up to ten times more potent HITubs (e.g., HITub-4). b) Straightforward, short, and high-yielding synthesis of HITub-4.